Back to Search Start Over

A prospective study to evaluate the clinical specificity of the cobasĀ® MPX test kit for screening for HIV RNA, HCV RNA, and HBV DNA in blood donation samples using the cobasĀ® 6800 system in HBV endemic areas

Authors :
Lei Zhou
Lin Wang
Xiaofang Gong
Xiaochun Liu
Yaxuan Zou
Yingying Wang
Jinfeng Zeng
Liang Zang
Source :
Journal of Clinical Virology Plus, Vol 5, Iss 1, Pp 100197- (2025)
Publication Year :
2025
Publisher :
Elsevier, 2025.

Abstract

Background: Nucleic acid testing (NAT) is widely used for screening blood donors for infectious diseases to enhance transfusion safety. Roche's advanced cobas® MPX assay detects human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using the cobas® 6800/5800 Systems, based on real-time PCR technology, providing improved sensitivity. This study aims to evaluate the clinical sensitivity and specificity of the cobas® MPX assay and its effectiveness in identifying infected donors in HBV endemic areas, particularly those with occult HBV infection (OBI). Materials and methods: A total of 12,067 donor samples from the Dalian Blood Center (DLBC, northern China) were tested for HIV, HCV, and HBV using both the cobas® MPX assay on the cobas® 6800 system and the previous generation cobas® TaqScreen MPX test v2.0 on the cobas s 201 system as the reference method. Testing was conducted using individual-donation testing (IDT) and primary pool of six donations (PP6), following the manufacturer's instructions and the operational procedures of the instruments. Samples with inconsistent results underwent repeated confirmation tests. Results: Cobas® MPX demonstrated 100.00 % overall percent agreement (95 % CI, 99.22 %-100.00 %) for IDT and 99.89 % (95 % CI, 99.82 %-99.95 %) for PP6. Kappa coefficients were 1.0 for IDT and 0.76 for PP6. Cobas® MPX specificity was 100.00 % (95 % CI, 99.22 %-100.00 %) for IDT and 99.99 % (95 % CI, 99.94 %-100.00 %) for PP6. Sensitivity was 100.00 % (95 % CI, 2.50 %-100.00 %) for IDT and 86.67 % (95 % CI, 68.36 %-95.64 %) for PP6. A total of 12 HBV NAT-yield cases were detected by cobas® MPX. Conclusion: Cobas® MPX demonstrated outstanding sensitivity and specificity in screening HIV, HCV, and HBV in routine blood donations, particularly enhancing occult HBV detection in endemic regions.

Details

Language :
English
ISSN :
26670380 and 62602268
Volume :
5
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Clinical Virology Plus
Publication Type :
Academic Journal
Accession number :
edsdoj.9ec334621bd9449688c54aae62602268
Document Type :
article
Full Text :
https://doi.org/10.1016/j.jcvp.2024.100197